Reckitt Benckiser Group Plc

The three-year trend is down. Headcount fell from roughly 40,000+ before the July 2024 strategy reset to about 36,000 after the Essential Home carve-out. Drivers were the transfer of six plants and their staff to Advent, management-layer reduction under Fuel for Growth (five layers cut to three), and shared-service consolidation.

Market capitalisation

Reckitt is a UK-headquartered, pure-play consumer health and hygiene company that is part-way through a deliberate portfolio contraction. It owns 11 "Powerbrands" that drive more than 80% of Core net revenue: Dettol, Lysol, Harpic, Finish, Vanish, Durex, Veet, Mucinex, Nurofen, Strepsils and Gaviscon.

Since the July 2024 strategy update, Reckitt has done the following:

• sold a 70% stake in its £1.9bn-revenue Essential Home household business to Advent International (completed 31 December 2025);

• returned £6.4bn to shareholders since July 2024;

• cut fixed costs from 20.9% to 19.4% of revenue in one year;

• reclassified Mead Johnson Nutrition (£2.1bn revenue) as non-core, with all options open.

Core Reckitt grew 5.2% LFL in 2025, at a 26.7% adjusted operating margin. Emerging Markets are now its largest area at 44% of Core revenue in H1 2026.

The investment case rests on three things: medium-term 4–5% Core growth, margin expansion, and a clean exit from Mead Johnson. That exit is weighed down by US NEC litigation, although the defence record has recently been strong.

---

What the company does

Reckitt develops, manufactures, markets and sells branded consumer health and hygiene products. Its own description of its purpose is to "protect, heal and nurture in the pursuit of a cleaner, healthier world" (company boilerplate, 2025–26 RNS). In its July 2024 Strategy Update and the FY2024/FY2025 reports, management set the ambition to become a "world-class consumer health and hygiene company" focused on high-growth, high-margin Powerbrands.

From 1 January 2026, reported operations are:

Business and revenue model

Reckitt's revenue is almost entirely product sales of branded fast-moving consumer goods (FMCG) and over-the-counter (OTC) medicines. It has:

• no material subscription revenue;

• no material licensing revenue. Minor brand-licensing income exists in some markets; not separately disclosed.

• a small service-type income stream from 2026: transitional manufacturing, distribution and services income from Vestacy (£248m of related-party income in H1 2026 under IAS 24);

• vendor loan note interest (£10m in H1 2026);

• a share of the Vestacy associate's result (a £23m loss in H1 2026).

Value-chain position

Reckitt is a vertically integrated brand owner. It handles:

• R&D, including medical and material science;

• regulatory affairs for OTC drugs and infant formula, which are FDA-regulated in the US;

• in-house manufacturing across a global plant network, supplemented by co-manufacturers;

• brand marketing (Brand Equity Investment was 14.6% of net revenue in FY2025);

• sales and distribution to retail customers.

It does not own retail. It sells through:

• mass grocery and hypermarkets;

• drugstores and pharmacies;

• e-commerce, which is material in China, where social e-commerce and new online launches drive growth;

• traditional trade (kiranas) in India and other emerging markets;

• hospital and clinical channels for MJN preterm products and for Biofreeze clinical sales.

Customer types and end-markets

End-markets served:

• consumer OTC healthcare (cold and flu, pain, digestive health);

• vitamins, minerals and supplements (VMS);

• sexual wellness and intimate care;

• hair removal;

• surface and personal disinfection;

• toilet care;

• automatic dishwashing;

• laundry stain removal;

• infant and specialised paediatric nutrition.

Independent characterisation

Reckitt is best understood as a two-speed consumer-health hybrid. Roughly half of Core revenue sits in OTC and VMS ("Self Care") and sexual wellness. These are structurally higher-growth and higher-margin categories with pharmacy-like regulatory moats.

The other half sits in hygiene and household categories (Germ Protection and Household Care). These carry strong brand shares but face private-label and promotional pressure, especially autodish in Europe.

The 2024–2026 programme has three parts:

• removing the lowest-growth home-care tail (Essential Home);

• ring-fencing the litigated nutrition asset (MJN);

• funding brand investment through fixed-cost reduction.

The mix shift toward Emerging Markets is pronounced. Emerging Markets delivered LFL growth of 14.6% in FY2025 and 8.5% in H1 2026, which makes the group more growth-geared but also more exposed to FX, geopolitical shocks (Middle East, Russia) and Chinese tax and regulatory changes such as the VAT on condoms.

Stated strategy (themes from AR2025 and the July 2024 Strategy Update)

1. Focus on Core Reckitt and Powerbrands. Eleven Powerbrands drive more than 80% of Core net revenue (reckitt.com).

2. A "simpler, more effective Reckitt."

   • New operating model from 1 Jan 2025.

   • Management layers cut from five to three.

   • Unified go-to-market.

3. Superior innovation rooted in medical and material science.

   • Category creation (Lysol Air Sanitizer, Mucinex 12HR Cold & Fever).

   • Premiumisation (Finish Ultimate Plus, Durex Intensity).

4. Geographic footprint leverage.

   • High-single-digit Emerging Markets growth targeted (H2 2025 call, 5 Mar 2026).

   • India and China as twin engines.

5. Fuel for Growth.

   • Fixed-cost reduction funding Brand Equity Investment.

   • Digital, AI and shared services.

6. Capital discipline and returns.

   • Progressive dividend (+5% a year in 2024–2026).

   • Ongoing buybacks.

   • Return of disposal proceeds.

   • Maintain A-grade credit metrics.

7. Portfolio reshaping.

   • Exit Essential Home (done).

   • MJN non-core with all options open.

   • Exit Russia Hygiene (pending).

Initiative register (last 24 months)

Strategy Update (Jul 2024)

• Description: defined Core Reckitt, the Essential Home exit, MJN as non-core and Fuel for Growth.

• Targets / metrics: medium-term Core LFL of 4–5%; fixed costs to 19% of revenue by end-2027.

• Status: in execution.

Fuel for Growth (Jul 2024–2027)

• Description: fixed-cost and organisation simplification; shared-service hubs; AI.

• Targets / metrics:

  • Fixed costs were 20.9% of revenue in FY2024 and 19.4% in FY2025. Management is now confident of going below 19% by end-2027.

  • Estimated one-off cash cost is about £1.0bn.

  • One-off costs were £179m in FY2025 and £108m in H1 2026.

• Status: ahead of plan. Management also sees additional efficiencies outside fixed costs within the same budget (H1 2026).

Brand Equity Investment step-up

• Description: higher marketing behind Powerbrands.

• Targets / metrics: BEI rose to 14.6% of revenue in FY2025 from 13.4%; 15.3% of Core + MJN revenue in H1 2026.

• Status: ongoing.

Essential Home divestment

• Description: 70% stake sold to Advent; 30% retained.

• Targets / metrics: completed 31 Dec 2025; £1.6bn special dividend.

• Status: done.

Russia Hygiene exit

• Description: sale to Arnest Management.

• Targets / metrics: about 1% of Core revenue; post-tax loss of about £175m.

• Status: expected completion H2 2026.

MJN strategic review

• Description: all options considered.

• Targets / metrics: no formal sale process (Barclays conference, 8 Sep 2026). Management will be pragmatic but will not accept a price requiring impairment.

• Status: open.

Capex and supply-chain programme

• Description: Wilson NC, Taicang, Nowy Dwór, Raposo, Bangplee.

• Targets / metrics: capex about 4% of revenue in 2026 (4.2% in 2025).

• Status: ongoing.

US transformation investment (Sep 2026)

• Description: up to US$600m over several years, covering the NJ R&D germ-protection hub and the doubled Wilson NC OTC plant.

• Targets / metrics: "Reckitt Focus On: North America" investor event on 19 Nov 2026.

• Status: announced.

Reckitt Focus On investor series (2025–26)

• Description: deep-dives on Areas and categories.

• Status: ongoing (Investor seminars, reckitt.com).

Digital science and AI programme

• Description: AI in R&D and functions. A July 2026 event showcased "digital science".

• Targets / metrics: faster innovation and pipeline expansion. Quantitative targets not disclosed.

• Status: ongoing.

Reckitt Catalyst

• Description: company programme expanded into the US in 2025–26. Its SXSW 2026 headline event featured Serena Williams.

• Status: ongoing.

Sustainability Ambitions 2030

• Description: 50% of net revenue from more sustainable products by 2030; net zero by 2040; science-based targets.

• Targets / metrics: 37.9% of revenue from more sustainable products in FY2025; 73% absolute reduction in operational GHG emissions.

• Status: in progress.

Share buybacks

• Description:

  • £1bn programme (2023–24).

  • £1bn programme announced 2025, completed in H1 2026.

  • New £500m programme over 12 months, started 5 Aug 2026. The first tranche of £150m with Citigroup is due by 11 Dec 2026.

• Status: ongoing.

Auditor decision

• Description: KPMG retained; the PwC transition was cancelled.

• Status: H1 2026.

Medium-term targets and guidance

Medium-term:

• Core Reckitt to consistently deliver +4% to +5% LFL net revenue growth.

• Consistent annual EPS growth and value creation.

• Fixed costs below 19% by end-2027.

FY2026 guidance (reiterated 29 Jul 2026):

• Core LFL +4% to +5%.

• MJN low-single-digit LFL.

• Core + MJN AOP margin of 24.9%–25.6%, with H2 "much stronger" than the H1 23.6%.

• Adjusted net finance expense £320m–£340m.

• Adjusted tax rate about 27%.

• Capex about 4% of revenue.

• Adjusted EPS diluted by the Essential Home disposal in 2026.

Input costs. Management modelled oil at US$110/bbl for the rest of 2026, implying a gross input-cost headwind of about £130–150m. The impact has since moderated (H1 2026).

Pricing models are standard retail and wholesale list pricing with trade promotion. Reckitt does not publish list prices. "Latest innovation year" refers to launches disclosed in FY2025 or H1 2026 results unless stated.

Core Reckitt — Self Care (FY2025 revenue £3,306m)

Mucinex — Powerbrand

• Description: US-centric cough, cold, chest congestion and sinus OTC range, including the Maximum Strength 12-hour guaifenesin franchise.

• Target customer: US and Canada adults and children.

• Latest innovation:

  • Mucinex 12HR Cold & Fever, launched Q2–H2 2026. The company describes it as the first FDA-approved long-lasting multi-symptom product in the category in over a decade.

  • Mucinex Sinus phenylephrine-free reformulation (2025), including Rapid+Clear and Sinus-Max.

  • Children's Mighty Chews Cold & Flu (2025).

• Flagship offerings: Mucinex 12HR, Mucinex Fast-Max, Mucinex DM.

• Recent performance: mid-to-high single-digit LFL decline in FY2025 on a weak season; returned to growth in Q2 2026.

Delsym

• Description: extended-release dextromethorphan cough syrup.

• Target customer: US families.

• Latest innovation: not separately disclosed.

• Flagship offerings: Delsym 12 Hour.

• Recent performance: part of the seasonal OTC pool.

Nurofen — Powerbrand

• Description: ibuprofen-based analgesics. Market leader across Europe and Australia.

• Target customer: adults and children (Nurofen for Children).

• Latest innovation: Nurofen Mini Liquid Capsules, extended into European markets in Q3 2025.

• Flagship offerings: Nurofen Express, Nurofen Joint & Back.

• Recent performance: double-digit growth in Emerging Markets in Q4 2025.

Strepsils — Powerbrand

• Description: medicated throat lozenges and sprays.

• Target customer: Europe, Emerging Markets and ANZ.

• Latest innovation:

  • Strepsils Cough Syrup, launched in Europe in Q3 2025.

  • Strepsils Cough Dual Action global rollout after its Poland launch (2026).

• Flagship offerings: Strepsils Original, Strepsils Intensive.

• Recent performance: mid-single-digit decline in FY2025 on cold and flu incidence.

Gaviscon — Powerbrand

• Description: alginate-based heartburn and reflux treatment.

• Target customer: Europe, ASEAN, LATAM, ANZ. Sold as "Lufta" in Brazil.

• Latest innovation:

  • Gaviscon Double Action rollout across Europe (2026).

  • LuftaGastroPro Double Action, Brazil (2025).

• Flagship offerings: Gaviscon Advance, Gaviscon Double Action.

• Recent performance: double-digit growth in Emerging Markets (FY2025); high-single-digit growth in Europe (FY2025).

Lemsip

• Description: hot-drink cold and flu remedies.

• Target customer: UK and Ireland.

• Latest innovation: not disclosed.

• Flagship offerings: Lemsip Max.

• Recent performance: seasonal.

Move Free

• Description: joint health supplements (glucosamine and others), from the 2012 Schiff acquisition.

• Target customer: US and China.

• Latest innovation: new launches in the US and China (2025–26).

• Flagship offerings: Move Free Ultra.

• Recent performance: strong; drove North America share gains in H1 2026.

MegaRed

• Description: krill-oil heart health supplements.

• Target customer: US and China.

• Latest innovation: China launches (2026).

• Flagship offerings: MegaRed Omega-3 Krill Oil.

• Recent performance: a growth driver in China.

Neuriva

• Description: brain-health supplements.

• Target customer: US adults.

• Latest innovation: innovations launched in North America (2025).

• Flagship offerings: Neuriva Plus.

• Recent performance: part of VMS, which grew double-digit in FY2025.

Airborne

• Description: immune-support supplements.

• Target customer: US.

• Latest innovation: not disclosed.

• Flagship offerings: Airborne Effervescent.

• Recent performance: surged more than 100% in 2020 (FY2020 RNS).

Digestive Advantage

• Description: probiotic supplements.

• Target customer: US.

• Latest innovation: not disclosed.

• Flagship offerings: not disclosed.

Biofreeze

• Description: menthol-based topical pain relief. Retail and clinical channels.

• Target customer: US clinics and retail.

• Latest innovation: innovations in North America (2025).

• Flagship offerings: Biofreeze Roll-On, Biofreeze Spray.

• Recent performance: underperforming. Brand intangibles were impaired by £175m in FY2025. Recoverable amount is £310m (US$426m).

Cepacol

• Description: sore-throat lozenges.

• Target customer: US.

• Latest innovation: not disclosed.

• Flagship offerings: Cepacol Extra Strength.

Dobendan / other local OTC

• Description: local throat and cough brands.

• Target customer: individual European markets.

• Latest innovation: not disclosed.

Clearasil (reported within Health historically; current category not disclosed)

• Description: acne skincare.

• Target customer: teens, in the US and Europe.

• Latest innovation: not disclosed.

• Flagship offerings: Clearasil Ultra.

Core Reckitt — Germ Protection (FY2025 revenue £3,224m)

Dettol — Powerbrand; now Reckitt's largest Powerbrand by net revenue

• Description: antiseptic liquid, soaps, body wash, surface and home disinfection, laundry sanitiser and appliance cleaners.

• Target customer: India, China, ASEAN, Middle East, Africa, Europe, ANZ.

• Latest innovation:

  • Dettol Activ Botany, a plant-based germ-protection line launched in China in early 2025 and rolled out to ASEAN and India in 2026.

  • Personal-care restage around 12-hour protection.

  • Washing Machine Cleaner and other appliance disinfection products.

• Flagship offerings: Dettol Antiseptic Liquid, Dettol Original Soap, Dettol Activ Botany.

• Recent performance: double-digit growth in FY2025; double-digit growth in H1 2026.

Lysol — Powerbrand

• Description: US disinfectant sprays, wipes and cleaners. Adjacent categories include Lysol Air Sanitizer and Lysol Laundry Sanitizer.

• Target customer: US and Canadian households and institutions.

• Latest innovation: Lysol Air Sanitizer, a category creation whose fragrance range was extended in 2025; Laundry Sanitizer extensions.

• Flagship offerings: Lysol Disinfectant Spray, Lysol Wipes.

• Recent performance: low-single-digit growth in FY2025; high-single-digit growth in North America in H1 2026.

Harpic — Powerbrand

• Description: toilet and bathroom cleaners.

• Target customer: India, MENARP, Europe.

• Latest innovation: not separately disclosed.

• Flagship offerings: Harpic Power Plus.

• Recent performance: mid-single-digit growth in FY2025, with double-digit growth in India and MENARP and a high-single-digit decline in Europe.

Sagrotan / Lizol / Napisan / Veja (local hygiene brands)

• Description: local-market equivalents for disinfection and surface care. Sagrotan in Germany, Lizol in India, Veja in Brazil.

• Target customer: individual markets.

• Latest innovation: not disclosed.

Mortein (APAC and other markets retained by Reckitt)

• Description: insect control.

• Target customer: APAC.

• Note: Mortein rights in North America, Europe and LATAM transferred to Essential Home/Vestacy. Category placement of the retained Mortein business is not disclosed.

Core Reckitt — Household Care (FY2025 revenue £2,189m)

Finish — Powerbrand; number one autodish brand in Europe

• Description: automatic dishwashing tablets, rinse aid and machine care.

• Target customer: Europe, North America, Emerging Markets (where autodish penetration is being developed).

• Latest innovation: formula upgrade to the top-tier Finish Ultimate Plus All in One (2025), which delivered double-digit growth for Ultimate Plus in Europe and Emerging Markets.

• Flagship offerings: Finish Ultimate Plus, Finish Quantum, Finish Powerball.

• Recent performance: flat in FY2025. Under promotional pressure in Europe in H1 2026. Grocery-channel softness in North America in Q2 2026.

Vanish — Powerbrand

• Description: laundry stain removers and fabric whiteners.

• Target customer: Europe, LATAM, China.

• Latest innovation: Vanish Turbo, a quick-wash and tough-stains formulation rolled out in Europe in 2026. It returned the brand to growth in Q2 2026.

• Flagship offerings: Vanish Oxi Action, Vanish Turbo.

• Recent performance: flat in FY2025; growing in Q2 2026.

Core Reckitt — Intimate Wellness (FY2025 revenue £1,515m)

Durex — Powerbrand; global condom leader

• Description: condoms, lubricants and sexual-wellness devices.

• Target customer: adults globally, with large exposure to China and India.

• Latest innovation:

  • Durex Intensity, described as the world's first nitrile condom. Launched in Europe and North America in 2025, with more than 5m units sold.

  • Hyaluronic Acid range extended to Air and Fetherlite in China.

  • Benzocaine condom upgrades.

• Flagship offerings: Durex Invisible, Durex Intensity, Durex Play.

• Recent performance: double-digit growth in FY2025. Broadly flat in H1 2026 because of the new China condom VAT and competition.

Veet — Powerbrand

• Description: depilatory creams, wax strips and hair-removal devices.

• Target customer: women globally.

• Latest innovation: social-first activation in 2026; product launches not separately disclosed.

• Flagship offerings: Veet Wax Strips, Veet Hair Removal Cream.

• Recent performance: double-digit growth in FY2025; high-single-digit growth in Europe in H1 2026.

Intima

• Description: feminine intimate hygiene. Mainly sold online in China.

• Target customer: Chinese women.

• Latest innovation: formula upgrade and travel-pack line extension (2025).

• Flagship offerings: not disclosed.

• Recent performance: net revenue close to doubling in FY2025.

K-Y

• Description: personal lubricants, acquired from Johnson & Johnson.

• Target customer: US and Europe.

• Latest innovation: lubricant portfolio upgrades (2025).

• Flagship offerings: K-Y Jelly.

Non-core — Mead Johnson Nutrition (FY2025 revenue £2,119m; AOP £433m)

Enfamil

• Description: infant formula, including Enfamil NeuroPro and Enfamil Gentlease. Preterm products include Enfamil Premature formula and human milk fortifiers, which are the subject of NEC claims.

• Target customer: US, LATAM and ASEAN; parents and hospitals.

• Latest innovation: rice-based products launched in the Philippines and Mexico (H1 2026).

• Note: preterm products are sold under physician supervision.

Enfagrow / Enfa A+

• Description: growing-up milks for toddlers.

• Target customer: ASEAN and LATAM.

• Latest innovation: not disclosed.

Nutramigen

• Description: hypoallergenic extensively hydrolysed formula for cow's-milk protein allergy.

• Target customer: US and international specialty segments.

• Latest innovation: drove price/mix in FY2025.

• Note: specialty and premium positioning.

PurAmino / Pregestimil / EnfaCare

• Description: amino-acid-based and specialty medical formulas.

• Target customer: clinical and hospital settings.

• Latest innovation: not disclosed.

WIC contracts (US)

• Description: state WIC programme supply.

• Target customer: low-income US families.

• Note: lower value per unit. Prioritised after the 2024 tornado.

Divested — Essential Home (reference only; 70% owned by Advent/Vestacy since 31 Dec 2025)

• Global brands: Air Wick, Calgon, Woolite, Cillit Bang, Resolve, Sole and Easy-Off.

• Mortein in North America, Europe and LATAM.

• About 75 other brands across more than 70 markets.

• FY2025 revenue £1,852m; AOP £379m (20.5% margin).

• Reckitt's continuing exposure is through:

  • its 30% B-share stake (carrying value £48m at 30 Jun 2026);

  • a US$300m vendor loan note at 9–12% interest (fair value £236m);

  • transitional manufacturing and service agreements.

Services

Reckitt offers no commercial service lines. The Vestacy Transitional Services revenue (£235m in H1 2026) is a temporary contract-manufacturing and distribution arrangement, not a strategic offering.